Tags : Programs


Lexeo Acquires Stelios to Expands its Gene Therapy Pipeline for

Shots: Lexeo acquires exclusive rights to three preclinical AAV-mediated gene therapy programs for the treatment of rare cardiac disorders, focused on TNNI3-associated HCM & ARVC The acquisition will complement and bolster LEXEO’s advanced pre-clinical gene therapy pipeline with the addition of three novel programs for rare cardiac diseases Additionally, preclinical results from the TNNI3-associated HCM […]Read More


BioMarin Pharmaceutical Signs an Agreement with Deep Genomics on Advancing

Shots: Deep Genomics will receive an undisclosed upfront payment and is eligible to receive development milestones, BioMarin will receive an exclusive option to obtain Deep Genomics’ rights to each program for development & commercialization Deep Genomics will use its AI drug discovery platform (The AI workbench) to identify & validate target mechanisms, lead candidates & […]Read More


Roche and Reverie Labs Collaborate to Advance Kinase Drug Discovery

Shots: Reverie Labs to receive up front and is eligible to receive pre/clinical, regulatory milestones, as well as royalties on Roche’s sales of drug candidates, emerges from the collaboration Reverie Labs will deploy its technology platform to perform virtual screening, hit-to-lead generation, and lead optimization on kinase inhibitor discovery programs, alongside scientists at Roche and […]Read More


Formycon To Update on its Biosimilar Programs

Formycon signs an agreement with Bioeq AG and manufacturing partner for resubmission of BLA for FYB201 project (biosimilar, ranibizumab). Bioeq AG is in talks with the US FDA for resubmission supporting manufacturing data in the H2’20 In Oct 2019, Formycon’s FYB202 (biosimilar, ustekinumab) has completed its P-I trial with its initiation of P-III trial in […]Read More


Prevail Signs an Agreement with Lonza to Develop and Manufacture

Shots: Pevail and Lonza to work collaboratively for process and analytical development plus large-scale production using the baculovirus/Sf9 process for late-stage clinical and commercial supply at Lonza’s GMP facility in Houston. Lonza to manufacture Prevail’s pipeline of novel AAV-based gene therapy programs for neurodegenerative diseases at its gene therapy center of excellence in Houston, TX […]Read More


Axovant Sciences Licenses Two Gene Therapy Programs from University of

Shots: Axovant acquires WW development and commercialization rights for AXO-AAV-GM1 and AXO-AAV-GM2 Program and will make payments to University of Massachusetts The focus of the agreement is to develop functional copies of HEXA, HEXB & GLB1 genes encoding the certain enzymes to treat Gm1 Gangliosidosis, Tay-Sachs and Sandhoff Diseases AXO-AAV-GM1 program is initiated for GLB1 gene using AAV vector for […]Read More